Evaluation of Trazodone in OSA-MCI

Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disease. Before progressing to AD, individuals may experience mild cognitive impairment (MCI). While these individuals with MCI have an increased risk of progressing to AD, emerging studies reveal that obstructive sleep apnea (OSA) is a risk factor for both MCI an well as AD. Thus, it is worthwhile to identify clinical management or interventions that retard the conversion of subjects with comorbid MCI and OSA and AD. A randomized, double-blind, placebo-controlled study proposed herein aims to examine the effect of trazodone on reducing level sST2 and protein markers that are associated with neurodegeneration in the plasma of subjects with comorbid OSA and MCI. In this 1-year study, 124 study participants will undergo a series of neurocognitive assessments.

NCT Number	NCT05209035
Lead Sponsor	Chinese University of Hong Kong Collaborators: Hong Kong University of Science and Technology
Conditions	Mild Cognitive Impairment, Obstructive Sleep Apnea
Enrollment	134 participants
Start Date	2022-05-10
Primary Completion	2025-05-02 (estimated)
Study Completion	2026-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-06